金迪克 (688670.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

Market Cap

CNY 1.85B

MomentumView details →

1D Return

−5.89%

YTD Return

—

RSI (14)

51.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

Market Cap

CNY 1.85B

RSI (14)

51.8

MomentumView details →

1D Return

−5.89%

YTD Return

—

ProfitabilityView details →

Gross Margin

62.21%

Net Margin

−166.13%

EBITDA Margin

−150.71%

ROE (TTM)

−17.02%

ROA (TTM)

−13.52%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−29.23%

EPS CAGR 3Y

−90.79%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.23

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

1.52x

Quick Ratio

1.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

−44.00%

Financials snapshotView financials →

Revenue (TTM)

110.32M

Net Income (TTM)

−183.27M

Op. CF (TTM)

−151.57M

Next earningsOct 23, 2026 →

Latest newsMore news →

Jindike announced its H1 2026 results: revenue fell 74.15% year-on-year to 0.9109 million yuan, and net loss attributable to shareholders widened to 51.0704 million yuan from 39.6531 million yuan a year earlier.15d ago

Similar companies

Mind Medicine (MindMed) Inc.MNMD Galapagos N.V.GLPG Damora Therapeutics, Inc.DMRA Immunocore Holdings plcIMCR Syndax Pharmaceuticals, Inc.SNDX Mabpharm Limited02181.HK Find similar companies →

Latest newsMore news →

Jindike announced its H1 2026 results: revenue fell 74.15% year-on-year to 0.9109 million yuan, and net loss attributable to shareholders widened to 51.0704 million yuan from 39.6531 million yuan a year earlier.15d ago